Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Duster340on Mar 22, 2024 10:45am
216 Views
Post# 35947071

RE:RE:(News Release)

RE:RE:(News Release)
MrMugsy wrote: Let me help Duster ...
1.  I highly doubt that anyone is trying to control this stock price ... don't think anyone ever tried to do that.  Would love to meet them.
2.  No information - true.
3.  The insider buying was timed quickly ... so likely as a message to investors.  They never buy in reoccurring events and it would be surprising to see it again this month.
4.  Good news - that's what the poster is all about.
5.  Uncertainty - sure !  If you don't have think skin by now, you won't have it.
6.  No need to touch it with any kind of pole - here's how investors are touching it and it isn't new ... they usually drive it up as they pick away and at some price, someone else offloads at market - making an exit for the doors, hitting new lows.  Drive it up for a bit and then someone offloads as they head for the doors.  Same old - same old.

Do you think you will ever again use that pole of yours to make a purchase ?      

: )
of course management was trying to control the s.p. with there buying it eased share holder panic and the further sell-off of shares that was the message to investors. it buys them more time to raise cash, not hard to put 2+2 together but who will finance them, how can they convince anyone with an unproven drug when potential financers look closely they will see the drug has already failed on an earlier attempt. i just do not see anyone stepping up it's a big risk with no guarantee of success. next week will be huge,  P2 was to begin the last week of march if not earlier. if there is no news next week ATE will sell-off. 
glta

<< Previous
Bullboard Posts
Next >>